Director, RaaS Research Group, Research as a Service (RaaS)

Research as a Service (RaaS)

Director, RaaS Research Group

Insightful Financial Models and Research Analysis

Connect to the right investors through smart and insightful financial models and research analysis.

Equity Bottom-Up

Neurotech International Ltd / Equity Bottom-Up

<div>
<div>
<div>
<div>
<h2>Neurotech International Ltd</h2>
<h3>Targeting treatment for autism spectrum disorder</h3>
<div>
<div>
<div>
<div>
<p>Neurotech International Ltd (ASX:NTI) is a biopharmaceutical company focused on clinical trials of NTI164, its proprietary whole plant medicinal cannabis strain, for use in the treatment of autism spectrum disorder (ASD). The company has recently completed a Phase I/II study of 14 candidates to assess the potential application of NTI164 in the treatment of ASD and found that 93% of participants had notable improvements to the severity of illness with no side effects. Neurotech is now planning a Phase II/III trial to further assess the efficacy of NTI164 and its long-term safety. The company has also announced successful preclinical research on NTI164 as a combination therapy for improving the efficacy of Diclofenac, an anti-inflammatory drug as well as Prednisone, a corticosteriod. Neurotech has applied for patents over NTI164 and has signalled that it sees an opportunity to expand applications to other neurological disorders such as Attention Deficit Hyperactivity Disorder (ADHD), Rett Syndrome, Multiple Sclerosis, Motor Neuron Disease, and Cerebral Palsy. The company is also seeking to commercialise its Mente device and therapy solution for assisting in increasing engagement and improving relaxation in autistic children with elevated Delta band brain activity.</p>
<div>
<div>
<div>
<div>
<h3>Business model</h3>
<p>Neurotech is seeking to develop its proprietary cannabis strain, NTI164, as a neurological application for the treatment of ASD in children. The company licenses NTI164 from Dolce Cann Global Ltd. The company has now completed its Phase I/II study, which was conducted by Professor Michael Fahey, the head of Paediatric Neurology at Monash Children’s Hospital in Melbourne. The study found that 93% of patients (14 candidates in the study) showed symptom improvement relating to the severity of the illness after 28 days of daily treatment of NTI164. This included 64% of patients with “much improved” symptoms, 29% with “minimally improved” symptoms and 7% with no change. The study also found that NTI164 was well tolerated across all doses and was granted HREC approval to continue for a further 54 weeks due to its positive therapeutic effects. NTI is now in discussions with the US Food and Drug Administration regarding a pre-Investigational New Drug application which it hopes to finalise by the end of this calendar year. Neurotech has also reported positive preclinical research which shows that NTI164 can improve Diclofenac (an anti-inflammatory drug used in the treatment of rheumatoid and osteoarthritis) efficacy at low doses. This potentially adds to NTI’s preclinical portfolio from a combination therapy perspective.</p>
<h3>Next steps include the outcome of Phase II/III studies</h3>
<p>The next steps for NTI are to initiate its Phase II/III trial to further assess the long-term safety and efficacy of NTI164 in the treatment of ASD with the potential to lead to drug registration. The company also has ambitions to extend NTI164 to potential treatment pathways for other neurological disorders including ADHD and Cerebral Palsy.</p>
<h3>Counting medicinal cannabis and paediatric pharma as peers</h3>
<p>We look to other medicinal cannabis companies such as Little Green Pharma (ASX:LDP), Emyria (ASX:EMD) and Cann Group (ASX:CAN) as peers for Neurotech being of similar size in market capitalisation and seeking to develop medicinal cannabis products. Neuren Pharmaceuticals (ASX:NEU) could also be counted as a peer given it is targeting paediatric neurological disorders with its drug therapies, although it should be noted that it is at a more advanced stage. Incannex (ASX:IHL) could also be considered a peer given its focus on combination therapies with off-patent pharmaceutical drugs and cannabinoids.</p>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>





Neurotech International Ltd
Targeting treatment for autism spectrum disorder




Neurotech International Ltd (ASX:NTI) is a biopharmaceutical company focused on clinical trials of NTI164, its proprietary whole plant medicinal cannabis strain, for use in the treatment of autism spectrum disorder (ASD). The company has recently completed a Phase I/II study of 14 candidates to assess the potential application of NTI164 in the treatment of ASD and found that 93% of participants had notable improvements to the severity of illness with no side effects. Neurotech is now planning a Phase II/III trial to further assess the efficacy of NTI164 and its long-term safety. The company has also announced successful preclinical research on NTI164 as a combination therapy for improving the efficacy of Diclofenac, an anti-inflammatory drug as well as Prednisone, a corticosteriod. Neurotech has applied for patents over NTI164 and has signalled that it sees an opportunity to expand applications to other neurological disorders such as Attention Deficit Hyperactivity Disorder (ADHD), Rett Syndrome, Multiple Sclerosis, Motor Neuron Disease, and Cerebral Palsy. The company is also seeking to commercialise its Mente device and therapy solution for assisting in increasing engagement and improving relaxation in autistic children with elevated Delta band brain activity.




Business model
Neurotech is seeking to develop its proprietary cannabis strain, NTI164, as a neurological application for the treatment of ASD in children. The company licenses NTI164 from Dolce Cann Global Ltd. The company has now completed its Phase I/II study, which was conducted by Professor Michael Fahey, the head of Paediatric Neurology at Monash Children’s Hospital in Melbourne. The study found that 93% of patients (14 candidates in the study) showed symptom improvement relating to the severity of the illness after 28 days of daily treatment of NTI164. This included 64% of patients with “much improved” symptoms, 29% with “minimally improved” symptoms and 7% with no change. The study also found that NTI164 was well tolerated across all doses and was granted HREC approval to continue for a further 54 weeks due to its positive therapeutic effects. NTI is now in discussions with the US Food and Drug Administration regarding a pre-Investigational New Drug application which it hopes to finalise by the end of this calendar year. Neurotech has also reported positive preclinical research which shows that NTI164 can improve Diclofenac (an anti-inflammatory drug used in the treatment of rheumatoid and osteoarthritis) efficacy at low doses. This potentially adds to NTI’s preclinical portfolio from a combination therapy perspective.
Next steps include the outcome of Phase II/III studies
The next steps for NTI are to initiate its Phase II/III trial to further assess the long-term safety and efficacy of NTI164 in the treatment of ASD with the potential to lead to drug registration. The company also has ambitions to extend NTI164 to potential treatment pathways for other neurological disorders including ADHD and Cerebral Palsy.
Counting medicinal cannabis and paediatric pharma as peers
We look to other medicinal cannabis companies such as Little Green Pharma (ASX:LDP), Emyria (ASX:EMD) and Cann Group (ASX:CAN) as peers for Neurotech being of similar size in market capitalisation and seeking to develop medicinal cannabis products. Neuren Pharmaceuticals (ASX:NEU) could also be counted as a peer given it is targeting paediatric neurological disorders with its drug therapies, although it should be noted that it is at a more advanced stage. Incannex (ASX:IHL) could also be considered a peer given its focus on combination therapies with off-patent pharmaceutical drugs and cannabinoids.













Neurotech International Ltd - Targeting Treatment for Autism Spectrum Disorder

Australia

Neurotech International Limited operates as a medical device and solutions company. The Company focuses on developing neuro-stimulation and neuro-diagnostic solutions. Neurotech International offers portable electroencephalographic medical devices for home use.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Neurotech International Ltd (NTI AU)

Neurotech International Ltd - Targeting Treatment for Autism Spectrum Disorder

Neurotech International Ltd Targeting treatment for autism spectrum disorder Neurotech International Ltd (ASX:NTI) is a biopharmaceutical...

Research as a Service (RaaS)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)